Our clients published preclinical data on NASH on Molecular Cancer Research
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on Molecular Cancer Research.
Title: “Inhibition of the cell death pathway in non-alcoholic steatohepatitis (NASH)-related hepatocarcinogenesis is associated with histone H4 lysine 16 deacetylation“
The results of the study identified a reduction of global and gene-specific histone H4K16 acetylation as a key pathophysiological mechanism contributing to the development of NASH-derived HCC, and emphasized the role of epigenetic alterations in the hepatocarcinogenic process.